Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Feb 6, 2026
- Accession no.
- 0001193125-26-041500
- Filed
- Feb 6, 2026
- Trade date
- Feb 4-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $152.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Common Stock | AGrant or awardAcquired | +73,000 | $0.00 | $0 | 371,661 | Direct | |
| Feb 4, 2026 | Common Stock | AGrant or awardAcquired | +144,600 | $0.00 | $0 | 516,261 | Direct | |
| Feb 6, 2026 | Common Stock | SSaleDisposed | −7,412 | $20.62 | −$152,835.44 | 508,849 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Common Stock | AGrant or awardAcquired | +440,000 | $20.43 | +$8,989,200 | 440,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.